How a population-based cohort of men estimate lifetime risk of prostate cancer in a survey before entering a prostate cancer screening trial in Sweden?
(2024) In BMJ Open 14(8).- Abstract
Objectives Investigating men's perceived lifetime risk of prostate cancer. Design Survey-based study to men invited for prostate-specific antigen (PSA) screening in the GÖTEBORG-2 trial between September 2015 and June 2020. Setting 38 775 men in the Gothenburg area, Sweden, were invited for PSA-Testing and participated in a survey. Participants 17 980 men participated in PSA-Testing, of whom 13 189 completed the survey. In addition, 1264 men answered the survey only. Interventions Before having the PSA-Test, men answered an electronic survey and estimated their lifetime risk of receiving a prostate cancer diagnosis on a visual analogue scale from 0% to 100%. Main outcome measures The primary outcome was the median lifetime risk... (More)
Objectives Investigating men's perceived lifetime risk of prostate cancer. Design Survey-based study to men invited for prostate-specific antigen (PSA) screening in the GÖTEBORG-2 trial between September 2015 and June 2020. Setting 38 775 men in the Gothenburg area, Sweden, were invited for PSA-Testing and participated in a survey. Participants 17 980 men participated in PSA-Testing, of whom 13 189 completed the survey. In addition, 1264 men answered the survey only. Interventions Before having the PSA-Test, men answered an electronic survey and estimated their lifetime risk of receiving a prostate cancer diagnosis on a visual analogue scale from 0% to 100%. Main outcome measures The primary outcome was the median lifetime risk estimation, which was compared with Wilcoxon test to an anticipated lifetime risk of 20% (based on GÖTEBORG-1 trial). The secondary outcome was to determine factors associated with risk estimation in a multivariable linear regression model: previous prostate examination, family history, physical exercise, healthy diet, comorbidity, alcohol consumption, smoking, education level, marital status, urinary symptoms and erectile dysfunction. Results Among PSA-Tested men, the median estimated lifetime risk of prostate cancer was 30% (IQR 19% to 50%), corresponding to a 10 percentage-points higher estimation compared with the anticipated risk (p<0.001). Family history of prostate cancer, moderate to severe urinary symptoms and mild to moderate erectile dysfunction were associated with >5 percentage-points higher risk estimation. Similar results were obtained for non-PSA-Tested men. Conclusions Most men overestimated their prostate cancer risk which underscores the importance of providing them accurate information about prostate cancer. Trial registration number ISRCTN94604465.
(Less)
- author
- Palmstedt, Emmeli ; Månsson, Marianne ; Kollberg, Karin Stinesen ; Carlsson, Sigrid LU ; Hellström, Mikael ; Wallström, Jonas ; Hugosson, Jonas and Arnsrud Godtman, Rebecka
- organization
- publishing date
- 2024-08
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- prostate, surveys and questionnaires, urological tumours
- in
- BMJ Open
- volume
- 14
- issue
- 8
- article number
- e083562
- publisher
- BMJ Publishing Group
- external identifiers
-
- pmid:39153780
- scopus:85201644501
- ISSN
- 2044-6055
- DOI
- 10.1136/bmjopen-2023-083562
- language
- English
- LU publication?
- yes
- id
- 0a7d9f39-aee0-427d-9d8c-a224a7377ca7
- date added to LUP
- 2024-10-30 14:29:40
- date last changed
- 2025-07-10 12:58:59
@article{0a7d9f39-aee0-427d-9d8c-a224a7377ca7,
abstract = {{<p>Objectives Investigating men's perceived lifetime risk of prostate cancer. Design Survey-based study to men invited for prostate-specific antigen (PSA) screening in the GÖTEBORG-2 trial between September 2015 and June 2020. Setting 38 775 men in the Gothenburg area, Sweden, were invited for PSA-Testing and participated in a survey. Participants 17 980 men participated in PSA-Testing, of whom 13 189 completed the survey. In addition, 1264 men answered the survey only. Interventions Before having the PSA-Test, men answered an electronic survey and estimated their lifetime risk of receiving a prostate cancer diagnosis on a visual analogue scale from 0% to 100%. Main outcome measures The primary outcome was the median lifetime risk estimation, which was compared with Wilcoxon test to an anticipated lifetime risk of 20% (based on GÖTEBORG-1 trial). The secondary outcome was to determine factors associated with risk estimation in a multivariable linear regression model: previous prostate examination, family history, physical exercise, healthy diet, comorbidity, alcohol consumption, smoking, education level, marital status, urinary symptoms and erectile dysfunction. Results Among PSA-Tested men, the median estimated lifetime risk of prostate cancer was 30% (IQR 19% to 50%), corresponding to a 10 percentage-points higher estimation compared with the anticipated risk (p<0.001). Family history of prostate cancer, moderate to severe urinary symptoms and mild to moderate erectile dysfunction were associated with >5 percentage-points higher risk estimation. Similar results were obtained for non-PSA-Tested men. Conclusions Most men overestimated their prostate cancer risk which underscores the importance of providing them accurate information about prostate cancer. Trial registration number ISRCTN94604465.</p>}},
author = {{Palmstedt, Emmeli and Månsson, Marianne and Kollberg, Karin Stinesen and Carlsson, Sigrid and Hellström, Mikael and Wallström, Jonas and Hugosson, Jonas and Arnsrud Godtman, Rebecka}},
issn = {{2044-6055}},
keywords = {{prostate; surveys and questionnaires; urological tumours}},
language = {{eng}},
number = {{8}},
publisher = {{BMJ Publishing Group}},
series = {{BMJ Open}},
title = {{How a population-based cohort of men estimate lifetime risk of prostate cancer in a survey before entering a prostate cancer screening trial in Sweden?}},
url = {{http://dx.doi.org/10.1136/bmjopen-2023-083562}},
doi = {{10.1136/bmjopen-2023-083562}},
volume = {{14}},
year = {{2024}},
}